{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-052141","form_type":"8-K","ticker":null,"cik":"0001735948","company_name":"Greenbrook TMS Inc.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.812610+00:00","generated_at":"2026-06-03T06:34:06.459268+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Greenbrook TMS FY 2023 revenue up 10% to $73.8M; net loss narrows to $49.3M","bullets":["Revenue $73.8M, +10% YoY; regional operating loss improved 56% to $2.7M.","Net loss $49.3M vs $88.3M; loss per share $1.25 diluted (prior $3.77).","Restructuring: closed 53 centers, achieved $23M annual cost savings target, $1M charges.","Expanded Spravato to 82 centers; launched medication management pilot at 9 centers.","Company changed to domestic issuer; restated quarterly financials from IFRS to US GAAP."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-052141","json":"https://secwatch.observer/filing/0001104659-24-052141.json","markdown":"https://secwatch.observer/filing/0001104659-24-052141.md","text":"https://secwatch.observer/filing/0001104659-24-052141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735948/000110465924052141/0001104659-24-052141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735948/000110465924052141/tm2411514d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:34:06.459268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec1b737a1d9e6b6f927e7c462ff8917f04407219","claim":"Greenbrook TMS Inc. reported the fiscal year ended December 31, 2023 results: revenue $73.8 million, net income $49.3 million, EPS $(1.25).","evidence_excerpt":"are in United States dollars, unless otherwise stated. FISCAL 2023 OPERATIONAL AND FINANCIAL HIGHLIGHTS · Consolidated revenue increased by 10% in Fiscal 2023 to a record $73.8 million, up $7 million as compared to the fiscal year ended December 31, 2022 (“ Fiscal 2022 ”) despite the closure of 53 treatment centers (approximately 29% of active treatment","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1735948/000110465924052141/0001104659-24-052141-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$73.8 million"},{"label":"Net income","value":"$49.3 million"},{"label":"EPS","value":"$(1.25)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}